Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 332

1.

Fluoxetine versus phenelzine in atypical depression.

Pande AC, Birkett M, Fechner-Bates S, Haskett RF, Greden JF.

Biol Psychiatry. 1996 Nov 15;40(10):1017-20.

PMID:
8915561
3.
4.

A comparison of fluvoxamine and fluoxetine in the treatment of major depression.

Rapaport M, Coccaro E, Sheline Y, Perse T, Holland P, Fabre L, Bradford D.

J Clin Psychopharmacol. 1996 Oct;16(5):373-8.

PMID:
8889909
5.
6.

Moclobemide versus fluoxetine in the treatment of inpatients with major depression.

Gattaz WF, Vogel P, Kick H, Kohnen R.

J Clin Psychopharmacol. 1995 Aug;15(4 Suppl 2):35S-40S.

PMID:
7593728
7.

Escitalopram in major depressive disorder: a multicenter, randomized, double-blind, fixed-dose, parallel trial in a Chinese population.

Mao PX, Tang YL, Jiang F, Shu L, Gu X, Li M, Qian M, Ma C, Mitchell PB, Cai ZJ.

Depress Anxiety. 2008;25(1):46-54.

PMID:
17149753
8.

Fluoxetine for acute treatment of depression in children and adolescents: a placebo-controlled, randomized clinical trial.

Emslie GJ, Heiligenstein JH, Wagner KD, Hoog SL, Ernest DE, Brown E, Nilsson M, Jacobson JG.

J Am Acad Child Adolesc Psychiatry. 2002 Oct;41(10):1205-15.

PMID:
12364842
9.

Antidepressant efficacy and quality of life in depression: a double-blind study with moclobemide and fluoxetine.

Lonnqvist J, Sintonen H, Syvälahti E, Appelberg B, Koskinen T, Mannikko T, Mehtonen OP, Naarala M, Sihvo S, Auvinen J, et al.

Acta Psychiatr Scand. 1994 Jun;89(6):363-9.

PMID:
8085464
10.

A double-blind comparison of moclobemide and fluoxetine in the treatment of depressive disorders.

Williams R, Edwards RA, Newburn GM, Mullen R, Menkes DB, Segkar C.

Int Clin Psychopharmacol. 1993 Jan;7(3-4):155-8.

PMID:
8468437
11.
12.

Reboxetine, a new noradrenaline selective antidepressant, is at least as effective as fluoxetine in the treatment of depression.

Andreoli V, Caillard V, Deo RS, Rybakowski JK, Versiani M.

J Clin Psychopharmacol. 2002 Aug;22(4):393-9.

PMID:
12172339
13.

Continuation and maintenance treatment of major depression with the monoamine oxidase inhibitor phenelzine: a double-blind placebo-controlled discontinuation study.

Robinson DS, Lerfald SC, Bennett B, Laux D, Devereaux E, Kayser A, Corcella J, Albright D.

Psychopharmacol Bull. 1991;27(1):31-9.

PMID:
1862204
14.

Fluoxetine versus amitriptyline in the treatment of major depression with associated anxiety (anxious depression): a double-blind comparison.

Versiani M, Ontiveros A, Mazzotti G, Ospina J, Dávila J, Mata S, Pacheco A, Plewes J, Tamura R, Palacios M.

Int Clin Psychopharmacol. 1999 Nov;14(6):321-7.

PMID:
10565798
15.

Double-blind comparison of fluoxetine and nortriptyline in the treatment of moderate to severe major depression.

Akhondzadeh S, Faraji H, Sadeghi M, Afkham K, Fakhrzadeh H, Kamalipour A.

J Clin Pharm Ther. 2003 Oct;28(5):379-84.

PMID:
14632962
16.
17.

Desipramine versus phenelzine in recurrent unipolar depression: clinical characteristics and treatment response.

Swann AC, Bowden CL, Rush AJ, Rhoades H, Rose R, Kobes R.

J Clin Psychopharmacol. 1997 Apr;17(2):78-83.

PMID:
10950467
18.
19.

Efficacy and response time to sertraline versus fluoxetine in the treatment of unipolar major depressive disorder.

Suri RA, Altshuler LL, Rasgon NL, Calcagno JL, Frye MA, Gitlin MJ, Hwang S, Zuckerbrow-Miller J.

J Clin Psychiatry. 2000 Dec;61(12):942-6.

PMID:
11206600
20.

Evaluation of eszopiclone discontinuation after cotherapy with fluoxetine for insomnia with coexisting depression.

Krystal A, Fava M, Rubens R, Wessel T, Caron J, Wilson P, Roth T, McCall WV.

J Clin Sleep Med. 2007 Feb 15;3(1):48-55.

PMID:
17557453

Supplemental Content

Support Center